Dihydroergotamine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dihydroergotamine" in English language version.

refsWebsite

Global rank English rank

18nih.gov

4^th place

9doi.org

2^nd place

3web.archive.org

1^st place

3semanticscholar.org

11^th place

8^th place

2books.google.com

3^rd place

1fda.gov

447^th place

338^th place

1in.gov.br

3,151^st place

5,932^nd place

1americanmigrainefoundation.org

low place

1unc.edu

1,538^th place

1,042^nd place

1migraineagain.com

low place

1europa.eu

68^th place

117^th place

americanmigrainefoundation.org

"Dihydroergotamine (DHE) for Migraine Treatment | AMF". American Migraine Foundation. Retrieved 18 August 2024.

books.google.com

Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 340–. ISBN 978-3-88763-075-1.
National Institute on Drug Abuse (1994). NIDA Research Monograph. DHEW publication. National Institute on Drug Abuse. p. 275. Retrieved 26 October 2024.

doi.org

Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH (April 2005). "Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature". Annals of Emergency Medicine. 45 (4): 393–401. doi:10.1016/j.annemergmed.2004.07.430. PMID 15795718.
Saper JR, Silberstein S, Dodick D, Rapoport A (November 2006). "DHE in the pharmacotherapy of migraine: potential for a larger role". Headache. 46 (Suppl 4): S212–S220. doi:10.1111/j.1526-4610.2006.00605.x. PMID 17078853. S2CID 34332034.
Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L (September 2003). "Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy". British Journal of Pharmacology. 140 (2): 277–284. doi:10.1038/sj.bjp.0705437. PMC 1574033. PMID 12970106.
Bigal ME, Tepper SJ (February 2003). "Ergotamine and dihydroergotamine: a review". Current Pain and Headache Reports. 7 (1): 55–62. doi:10.1007/s11916-003-0011-7. PMID 12525272. S2CID 23124461.
Silberstein SD, McCrory DC (February 2003). "Ergotamine and dihydroergotamine: history, pharmacology, and efficacy". Headache. 43 (2): 144–166. doi:10.1046/j.1526-4610.2003.03034.x. PMID 12558771. S2CID 21356727.
Cavero I, Guillon JM (2014). "Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy". Journal of Pharmacological and Toxicological Methods. 69 (2): 150–161. doi:10.1016/j.vascn.2013.12.004. PMID 24361689.
Gumpper RH, Roth BL (January 2024). "Psychedelics: preclinical insights provide directions for future research". Neuropsychopharmacology. 49 (1): 119–127. doi:10.1038/s41386-023-01567-7. PMID 36932180.
Silberstein SD, Shrewsbury SB, Hoekman J (January 2020). "Dihydroergotamine (DHE) - Then and Now: A Narrative Review". Headache. 60 (1): 40–57. doi:10.1111/head.13700. PMC 7003832. PMID 31737909.
Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ (2020). "Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations". Journal of Pain Research. 13: 859–864. doi:10.2147/JPR.S203650. PMC 7200221. PMID 32431533.

europa.eu

ema.europa.eu

Restrictions on use of medicines containing ergot derivatives (EMA 2013) Archived 20 June 2018 at the Wayback Machine, Retrieved 3 August 2014

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

in.gov.br

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023.

migraineagain.com

"Dihydroergotamine (DHE) for Migraine Relief: Are You a Good Candidate? What to Know". MigraineAgain.com. Retrieved 18 August 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH (April 2005). "Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature". Annals of Emergency Medicine. 45 (4): 393–401. doi:10.1016/j.annemergmed.2004.07.430. PMID 15795718.
Saper JR, Silberstein S, Dodick D, Rapoport A (November 2006). "DHE in the pharmacotherapy of migraine: potential for a larger role". Headache. 46 (Suppl 4): S212–S220. doi:10.1111/j.1526-4610.2006.00605.x. PMID 17078853. S2CID 34332034.
Hauser JM, Azzam JS, Kasi A (2024). "Antiemetic Medications". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30335336. Retrieved 18 August 2024.
Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L (September 2003). "Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy". British Journal of Pharmacology. 140 (2): 277–284. doi:10.1038/sj.bjp.0705437. PMC 1574033. PMID 12970106.
Bigal ME, Tepper SJ (February 2003). "Ergotamine and dihydroergotamine: a review". Current Pain and Headache Reports. 7 (1): 55–62. doi:10.1007/s11916-003-0011-7. PMID 12525272. S2CID 23124461.
Silberstein SD, McCrory DC (February 2003). "Ergotamine and dihydroergotamine: history, pharmacology, and efficacy". Headache. 43 (2): 144–166. doi:10.1046/j.1526-4610.2003.03034.x. PMID 12558771. S2CID 21356727.
Cavero I, Guillon JM (2014). "Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy". Journal of Pharmacological and Toxicological Methods. 69 (2): 150–161. doi:10.1016/j.vascn.2013.12.004. PMID 24361689.
Gumpper RH, Roth BL (January 2024). "Psychedelics: preclinical insights provide directions for future research". Neuropsychopharmacology. 49 (1): 119–127. doi:10.1038/s41386-023-01567-7. PMID 36932180.
Silberstein SD, Shrewsbury SB, Hoekman J (January 2020). "Dihydroergotamine (DHE) - Then and Now: A Narrative Review". Headache. 60 (1): 40–57. doi:10.1111/head.13700. PMC 7003832. PMID 31737909.
Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ (2020). "Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations". Journal of Pain Research. 13: 859–864. doi:10.2147/JPR.S203650. PMC 7200221. PMID 32431533.

dailymed.nlm.nih.gov

"D.H.E. 45- dihydroergotamine mesylate injection, solution". DailyMed. Retrieved 31 October 2021.
"Migranal- dihydroergotamine mesylate spray". DailyMed. Retrieved 31 October 2021.
"Dromelate- dihydroergotamine mesylate injection, solution". DailyMed. Retrieved 31 October 2021.
"Trudhesa- dihydroergotamine mesylate spray, metered". DailyMed. Retrieved 31 October 2021.

ncbi.nlm.nih.gov

Hauser JM, Azzam JS, Kasi A (2024). "Antiemetic Medications". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30335336. Retrieved 18 August 2024.
Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L (September 2003). "Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy". British Journal of Pharmacology. 140 (2): 277–284. doi:10.1038/sj.bjp.0705437. PMC 1574033. PMID 12970106.
Silberstein SD, Shrewsbury SB, Hoekman J (January 2020). "Dihydroergotamine (DHE) - Then and Now: A Narrative Review". Headache. 60 (1): 40–57. doi:10.1111/head.13700. PMC 7003832. PMID 31737909.
Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ (2020). "Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations". Journal of Pain Research. 13: 859–864. doi:10.2147/JPR.S203650. PMC 7200221. PMID 32431533.

semanticscholar.org

api.semanticscholar.org

Saper JR, Silberstein S, Dodick D, Rapoport A (November 2006). "DHE in the pharmacotherapy of migraine: potential for a larger role". Headache. 46 (Suppl 4): S212–S220. doi:10.1111/j.1526-4610.2006.00605.x. PMID 17078853. S2CID 34332034.
Bigal ME, Tepper SJ (February 2003). "Ergotamine and dihydroergotamine: a review". Current Pain and Headache Reports. 7 (1): 55–62. doi:10.1007/s11916-003-0011-7. PMID 12525272. S2CID 23124461.
Silberstein SD, McCrory DC (February 2003). "Ergotamine and dihydroergotamine: history, pharmacology, and efficacy". Headache. 43 (2): 144–166. doi:10.1046/j.1526-4610.2003.03034.x. PMID 12558771. S2CID 21356727.

unc.edu

pdsp.unc.edu

"Ergotamine search results". PDSP K_i Database. University of North Carolina Chapel Hill. Archived from the original on 13 April 2021. Retrieved 15 January 2022.

web.archive.org

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023.
"Ergotamine search results". PDSP K_i Database. University of North Carolina Chapel Hill. Archived from the original on 13 April 2021. Retrieved 15 January 2022.
Restrictions on use of medicines containing ergot derivatives (EMA 2013) Archived 20 June 2018 at the Wayback Machine, Retrieved 3 August 2014